Kabra Drugs books ₹92.74 cr revenue after a year of zero sales
The nano-cap swung to a ₹4.96 cr profit after diversifying into new manufacturing. The full-year revenue now exceeds the company's entire market capitalisation.
— 1 earlier story on Kabra Drugs Ltd. →What's new
- Annual revenue jumped from zero to ₹92.74 cr.
- Net profit of ₹4.96 cr, reversing a loss of ₹1.08 cr.
- Q4 operations generated over ₹35 cr, the bulk of the annual revenue.
Why this matters
This is a complete business transformation packed into a single fiscal year. The company moved from zero revenue to ₹92.74 cr, a figure that now exceeds its entire ₹59 cr market capitalisation.
What we're watching
- Whether the new manufacturing sectors can sustain revenue momentum into FY27.
- Details on the company's order pipeline and client concentration.
- How the concessional tax regime impacts future net profitability.
The full read
Kabra Drugs went from ₹0 in revenue to ₹92.74 crore in a single year. The catalyst: a strategic pivot into new manufacturing sectors that only began generating sales late in the year. Q4 alone contributed over ₹35 crore, meaning the majority of the annual top line arrived in the final quarter. Net profit flipped to ₹4.96 crore from a ₹1.08 crore loss. Auditors signed off cleanly, and the company has shifted to a concessional tax regime. For a nano-cap with a ₹59 crore market cap, the revenue now exceeds the entire equity value. Whether the new lines are a one-off spike or the beginning of a sustainable business is the open question. The transition happened too late in the year to know.
Questions answered
- What drove the revenue from zero to ₹92.74 cr?
- The company diversified into new manufacturing sectors, which began contributing significantly in the fourth quarter. Q4 alone accounted for over ₹35 cr of the full-year total.
- What does the unmodified audit opinion signal?
- The auditors found no material misstatements in the financials, lending credibility to the reported turnaround figures and the new revenue base.
- How does the result compare to the company's market size?
- Kabra Drugs has a market capitalisation of about ₹59 cr. The full-year revenue of ₹92.74 cr now exceeds the entire market value of the company.
- What is the concessional tax regime?
- The board confirmed the company has transitioned to a concessional tax regime. This typically lowers the effective tax rate, which would directly boost net profit margins on the new revenue.
Story so far
All notes on KABRADG →- 29 May 2026 · 10:21 PM IST Kabra Drugs books ₹92.74 cr revenue after a year of zero sales
- 1d ago Kabra Drugs posts ₹92.74 cr revenue after a year of nil sales